CSL lowers prices in Trump MFN deal

CSL has signed a Most Favoured Nation agreement with the United States as part of the latest tranche of pharmas to do so, and reiterated its investment in US manufacturing.

Under the agreement with the US Department of Health and Human Services, CSL will provide the Medicaid program with access to its current medicines at prices comparable to those available in other developed countries and will also similarly price any newly launched therapies for all payers in the US.

"At CSL, our focus has always been the patients who depend on our therapies," CSL Global Chief Commercial Officer, Diego Sacristan, said.